RemeGen came into this Q3 2026 print with a bargain label attached, trading on a P/E of 4.7x and sitting well below some valuation estimates. The fresh numbers tell a more complicated story. Management reported Q3 revenue of ¥910.5m and basic earnings per share of ¥1.09, a sharp comedown from the prior quarter’s outsized figures. The share price closed at HK$64.85 on 30 October, barely moved over the past week yet still down meaningfully over one and three months, which shows traders are cautious while the earnings thesis is being re priced.
Like the RemeGen story but worried that a low P/E could still mask earnings risk? Compare this set up with 197 high quality undervalued stocks, which pairs compressed valuations with stronger fundamentals.
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): ¥910.5m vs. ¥621.9m (up about 46%)
- Net Income, excl. extra items (Q3 2026 vs. Q3 2025): ¥610.9m vs. a loss of ¥101.1m (swing into profit)
- Basic EPS (Q3 2026 vs. Q3 2025): ¥1.09 vs. a loss of ¥0.18 per share (return to positive earnings per share)
- R&D Pipeline Scale (Q2 2026 vs. Q2 2025): Phase I: 6 vs. 4 products; Phase II: 8 vs. 11 products; Phase III: 10 vs. 2 products; Pre registration: 10 vs. 4 products (pipeline mix shifted toward later stage assets)
Ask Charlie what makes RemeGen’s low P/E look risky.
RemeGen bull case leans on profit swing
For anyone backing RemeGen as a broad oncology and autoimmune platform, this quarter gives some support. Sales reached ¥910.5m, well ahead of last year, and net income shifted from a loss of ¥101.1m to ¥610.9m. That is a clean move back into the black. The pipeline mix also leans more toward Phase III and pre registration projects, which fits a story where late stage assets start to matter more than early science for the earnings profile.
RemeGen bear case eyes volatility in earnings
Concerned about execution risk, you still have plenty to point to. Management described the latest profit as a comedown from an unusually strong prior quarter, which flags earnings volatility. The share price is roughly flat over 7 days but down about 16% over one month and 21% over three months, suggesting investors remain cautious despite the swing into profit. A larger tilt toward late stage trials also raises the stakes if future clinical or regulatory events do not break in RemeGen’s favour.
Do analysts think this cleaner swing back into profit at RemeGen is sustainable or a blip tied to one strong quarter? Check the consensus price target analysis for RemeGen.
Hunt For Mispriced Earnings Stories
RemeGen just reminded you that a return to profit does not always clean up the share price story overnight. The real opportunity is spotting stocks that could be undervalued before any valuation gap is addressed.
- Company 1 - 30% below our estimate - builds contract research and manufacturing capacity that large drug developers rely on for outsourced complex projects.
- Company 2 - 41% below our estimate - adds sauna and thermal wellness production lines aimed at health focused consumers upgrading home and professional relaxation spaces.
- Company 3 - 20% below our estimate - shifts from export heavy fuel shipments toward a retail and marketing network serving rising local demand for refined products.
Those are three of them. See every one of the 197 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com